Allogene Therapeutics (ALLO) Q3 2026 earnings review
Allogene raises research spending, but its trial timelines stand still
Allogene Therapeutics, a developer of off-the-shelf cell therapies for cancer and autoimmune disease, stepped up research spending while keeping its clinical deadlines in place. Research costs rose 35% from a year ago to $42 million as its main lymphoma study added patients, yet total expenses of $55 million stayed well below what the company's own plan pointed to for the second half. Chief executive Zachary Roberts set a November 9 release date for early autoimmune trial data, while by our math the unchanged annual cost plan leaves $73 million in spending for the fourth quarter.
| Research and development expenses | $41.9M +35% from a year ago |
|---|---|
| Net loss | $50.4M $0.15 per share vs $0.19 a year ago |
| Cash and investments | $388.9M runway projected into 2029 |
| Full-year GAAP expense outlook | Unchanged ~$225M, leaving $73M for Q4 by our math |
⚖️ Verdict: ⚪ Neutral
The story is unchanged because this quarter brought no new clinical results and left every major trial schedule where it stood. Scheduling the autoimmune readout for next week eases a timing delay after two quiet quarters, and cash burn ran below the company's full-year pace. The bad news: opening cancer clinics ahead of schedule still has not pulled forward the end-of-2027 enrollment completion target, and paststock sales pushed the share count up 56% from a year ago.
The question now is whether the expanding network of cancer clinics is actually enrolling lymphoma patients fast enough to beat the 2027 deadline, or if clinic openings are outrunning patient sign-ups. If clinics convert screened patients quickly, management can pull its survival readout forward; if conversion lags, timelines could slip again toward the 2029 cash limit. The next clinical update in mid-2027 and any disclosed patient counts in the annual report will tell.
🐂 Bull Case
Autoimmune Trial Data Arrives on November 9
Allogene develops ALLO-329, an off-the-shelf engineered cell therapy for autoimmune diseases such as lupus and scleroderma. It uses Dagger, a technology built to stop a patient's immune system from rejecting donor cells. Chief executive Zachary Roberts wants the drug to work "with less reliance on chemotherapy-based conditioning", which doctors normally use to clear a patient's existing immune cells before treatment.
After holding back details for two quarters, the biotechnology group scheduled a clinical presentation for November 9, 2026. The update covers an "expanded patient population, longer follow-up and results across three dose levels and three LD approaches", including patients who received no chemotherapy at all. Setting a firm date after earlier delays eases the wait, because investors can finally compare responses across chemotherapy levels.
What to watch: patient response rates in the no-chemotherapy and single-drug cohorts on November 9. Strong clinical activity without heavy chemotherapy would separate ALLO-329 from rival cell therapies that require toxic pre-treatment.
Research Spending Accelerates Behind the Lead Trial
Cema-cel is Allogene's lead off-the-shelf cell therapy for large B-cell lymphoma, a blood cancer. The company is testing it in ALPHA3, a trial that treats patients right after initial therapy if a blood test still finds minimal residual disease (MRD), meaning tiny traces of cancer. Most lymphoma patients receive care at local community clinics rather than big hospitals.
Research and development spending jumped 34.6% from a year ago to $41.9 million, climbing 36.5% from last quarter as patient screening and clinic participation grew. Allogene said early trial experience proved that community clinics with little or no cell-therapy history can give cema-cel to outpatients. Putting money directly into clinic activity matters because community doctors treat four out of five first-line lymphoma patients.
What to watch: the exact count of active trial clinics in the full-year report against the 100-site year-end target. Hitting that goal would confirm that community cancer centers are signing up at the planned pace.
Positives this quarter didn't test
Two regulatory advantages supporting the lead lymphoma trial remained intact this quarter without new events to test them.
- Blood-test treatment trigger: regulators increasingly accept circulating tumor DNA tests to select high-risk patients; ALPHA3's mid-2027 interim readout will test whether clearing those traces delays cancer relapse.
- Fast-track regulatory status: the Food and Drug Administration granted Regenerative Medicine Advanced Therapy and Fast Track designations in July 2026; their value will show when Allogene discusses approval filing timelines ahead of the mid-2028 primary readout.
🐻 Bear Case
More Clinics Have Not Pulled Timelines Forward
Allogene needs to enroll about 220 blood-test-positive lymphoma patients into the ALPHA3 trial. Last quarter, management said it passed 80 active clinics six months ahead of schedule and raised its year-end target to about 100 clinics. This quarter, the release highlighted "brisk enrollment in the Asia-Pacific region" and rising screening activity across its growing network.
Yet the press release did not disclose the current number of active clinics or how many patients have entered the trial. More importantly, Allogene left both major trial deadlines unchanged: it still expects to finish enrollment by the end of 2027 and report interim survival data in mid-2027. Opening clinics early helps only if those clinics actually find and enroll eligible patients.
What to watch: any disclosed count of randomized patients or a tighter enrollment window on the conference call. Keeping the end-of-2027 completion target once 100 clinics are open would indicate that each clinic is enrolling fewer patients than hoped.
Share Count Jumps While Cost Plan Looks Padded
Because Allogene has no approved drugs on the market, it funds its clinical trials by selling stock and drawing down cash. The company sold shares through a public offering in April and an ongoing stock-sale program earlier this year. Meanwhile, management maintained its full-year plan for total operating expenses at about $225 million.
- Weighted-average share count: 346.1 million, up 55.9% from a year ago and up 5.2% from last quarter
- Third-quarter GAAP operating expenses: $54.8 million, or 14.0% below the second-half pace implied by the annual outlook by our math
- Implied fourth-quarter GAAP operating expenses: $72.6 million by our math, a 71.1% jump from a year ago
Last year, full-year expenses finished 9.0% below management's final target by our math. Leaving the $225 million target unchanged after three quarters of lower spending suggests the cost plan is padded rather than a true forecast.
What to watch: fourth-quarter operating expenses and share count in the annual report. Landing well below $72.6 million would confirm that management routinely overstates its annual cost targets.
Risks this quarter didn't answer
Four standing risks around clinical outcomes, patent licences, rival therapies, and executive roles received no new resolution in the release.
- Survival benefit in ALPHA3: clearing cancer traces at day 45 does not guarantee patients live longer without relapse; the mid-2027 interim readout is the first test.
- Patent arbitration over gene-editing tools: Thermo Fisher's challenge to Cellectis licences underpinning cema-cel and CD70 drugs went unmentioned in the release; the quarterly 10-Q filing will carry any legal update.
- Rival blood-cancer treatments: Roberts noted that "CAR T has transformed what's possible in medicine, but toxicity and treatment complexity have kept its full potential out of reach for too many patients"; a survey of 152 doctors at the December hematology meeting will test how doctors view off-the-shelf cell therapy against competing antibodies.
- Chief medical officer vacancy: Roberts took over as chief executive in July while keeping interim medical duties; the release named no permanent replacement.
👓 Other Themes
Early Commercial Hiring and Lung Cancer Research
Allogene has begun "laying the groundwork for potential commercialization of cema-cel" by hiring Rocio Manghani as Vice President of Market Access to handle insurer coverage and clinic readiness. Separately, scientists presented early laboratory data on a dual DLL3/CD70 cell therapy for small cell lung cancer, showing that Dagger technology can protect other engineered cells from immune rejection.
💲 Other KPIs
Cash and investments fell by $34.7 million, or 8.2%, from $423.6 million at the end of June, as the drug developer funded its ongoing clinical trials. After raising $200.4 million in gross proceeds from a stock offering in April, the balance remains well above the $258.3 million held at the end of 2025.
Overhead costs dropped 38.3% from last quarter and 6.4% from a year ago. Last quarter included $7.7 million in one-time severance and stock awards for the chief executive transition; stripping that out by our math, underlying overhead slipped 2.1% from the second quarter. Stock-based pay made up $4.2 million of this quarter's total.
Total liabilities edged up 4.3% from $113.9 million in the second quarter as research activity expanded, but remain 3.7% lower than the $123.4 million recorded at the end of 2025. With $388.9 million in cash and investments, the balance sheet carries more than three times as much cash as total obligations.
🔮 Guidance
Unchanged. The full-year plan still calls for about $225 million in total operating expenses, up 7.5% from 2025 by our math. Because the first three quarters totaled $152.4 million, the outlook leaves $72.6 million for the fourth quarter by our math, a 32.4% jump from the third quarter. Last year, actual spending finished 9.0% below the final annual forecast.
Unchanged. Management kept its cash-based operating expense forecast at about $165 million after raising it from $150 million in the first quarter. Excluding stock-based pay, Allogene has spent $124.7 million over the first nine months by our math, which leaves $40.3 million for the fourth quarter if the target is met exactly.
Unchanged. The biotech group still expects about $35 million in non-cash employee stock awards for the full year, down from $37.6 million in 2025. After recording $8.3 million in the first quarter, $12.4 million in the second, and $7.0 million in the third, the plan leaves $7.3 million for the fourth quarter by our math.
Unchanged. Allogene continues to project that its $388.9 million in cash and investments will fund operations "into 2029", excluding any business development deals. That timeline covers the mid-2027 interim and mid-2028 primary survival readouts for the ALPHA3 lymphoma trial, leaving little room if enrollment delays push the study past 2028.
❓ Key Questions
How many patients and clinics are active in ALPHA3?
Allogene previously targeted about 100 active clinics by year-end after passing 80 in July, yet gave no clinic or patient count in the release. Investors need to know how many clinics are open and how fast they are enrolling the 220 required patients.
Why does the cost plan imply a fourth-quarter jump?
Holding the $225 million GAAP expense target leaves $72.6 million for the fourth quarter by our math, up from $54.8 million in the third. Meanwhile, the $165 million cash expense and $35 million stock-pay targets sum to $200 million, leaving a $25 million gap.
What is the status of the Cellectis patent arbitration?
Earlier filings disclosed that Thermo Fisher challenged Cellectis patent licences that underpin cema-cel and Allogene's CD70 programs. The earnings release did not mention the dispute, leaving open whether the arbitration threatens commercial rights or requires new royalty payments.
Has Allogene used its stock-sale program since June?
Weighted-average diluted shares rose by 17.2 million from the second quarter to 346.1 million. While the full-quarter weight of April's stock offering explains much of the increase, investors need the quarterly filing to check whether Allogene tapped its $135 million at-the-market facility.